Sofia Giorgetti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2125904/publications.pdf

Version: 2024-02-01

91 papers	3,534 citations	136950 32 h-index	155660 55 g-index
94 all docs	94 docs citations	94 times ranked	3221 citing authors

#	Article	IF	Citations
1	The corona of proteinâ€“gold nanoparticle systems: the role of ionic strength. Physical Chemistry Chemical Physics, 2022, 24, 1630-1637.	2.8	5
2	Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms. Frontiers in Molecular Biosciences, 2022, 9, 830006.	3.5	11
3	Topologically non-trivial metal-organic assemblies inhibit Î²2-microglobulin amyloidogenesis. Cell Reports Physical Science, 2021, 2, 100477.	5.6	1
4	Clinical ApoAâ€IV amyloid is associated with fibrillogenic signal sequence. Journal of Pathology, 2021, 255, 311-318.	4.5	4
5	S-Homocysteinylation effects on transthyretin: worsening of cardiomyopathy onset. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129453.	2.4	5
6	Insights into a Protein-Nanoparticle System by Paramagnetic Perturbation NMR Spectroscopy. Molecules, 2020, 25, 5187.	3.8	7
7	Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils. Journal of Biological Chemistry, 2020, 295, 11379-11387.	3.4	12
8	Crtap and p3h1 knock out zebrafish support defective collagen chaperoning as the cause of their osteogenesis imperfecta phenotype. Matrix Biology, 2020, 90, 40-60.	3.6	28
9	Exploring exchange processes in proteins by paramagnetic perturbation of NMR spectra. Physical Chemistry Chemical Physics, 2020, 22, 6247-6259.	2.8	5
10	C. elegans expressing D76N Î²2-microglobulin: a model for in vivo screening of drug candidates targeting amyloidosis. Scientific Reports, 2019, 9, 19960.	3.3	14
11	Interference of citrate-stabilized gold nanoparticles with Î²2-microglobulin oligomeric association. Chemical Communications, 2018, 54, 5422-5425.	4.1	11
12	Oleuropein aglycone: A polyphenol with different targets against amyloid toxicity. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 1432-1442.	2.4	30
13	Targeting Amyloid Aggregation: An Overview of Strategies and Mechanisms. International Journal of Molecular Sciences, 2018, 19, 2677.	4.1	103
14	Plasminogen activation triggers transthyretin amyloidogenesis in vitro. Journal of Biological Chemistry, 2018, 293, 14192-14199.	3.4	68
15	A FTIR microspectroscopy study of the structural and biochemical perturbations induced by natively folded and aggregated transthyretin in HL-1 cardiomyocytes. Scientific Reports, 2018, 8, 12508.	3.3	31
16	The interaction of Î²2-microglobulin with gold nanoparticles: impact of coating, charge and size. Journal of Materials Chemistry B, 2018, 6, 5964-5974.	5.8	7
17	Citrate-stabilized gold nanoparticles hinder fibrillogenesis of a pathological variant of Î²2-microglobulin. Nanoscale, 2017, 9, 3941-3951.	5.6	26
18	A specific nanobody prevents amyloidogenesis of D76N Î²2-microglobulin in vitro and modifies its tissue distribution in vivo. Scientific Reports, 2017, 7, 46711.	3.3	18

#	Article	IF	Citations
19	Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel. Scientific Reports, 2017, 7, 182.	3.3	31
20	Misidentification of transthyretin and immunoglobulin variants by proteomics due to methyl lysine formation in formalin-fixed paraffin-embedded amyloid tissue. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 229-237.	3.0	8
21	Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies. Journal of Proteomics, 2017, 165, 113-118.	2.4	14
22	Short-Chain Alkanethiol Coating for Small-Size Gold Nanoparticles Supporting Protein Stability. Magnetochemistry, 2017, 3, 40.	2.4	4
23	In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. Scientific Reports, 2016, 6, 29096.	3.3	63
24	Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes. Biophysical Journal, 2016, 111, 2024-2038.	0.5	19
25	Amyloid persistence in decellularized liver: biochemical and histopathological characterization. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 1-7.	3.0	25
26	Molecular insights into cell toxicity of a novel familial amyloidogenic variant of Î²2â€microglobulin. Journal of Cellular and Molecular Medicine, 2016, 20, 1443-1456.	3.6	23
27	Co-fibrillogenesis of Wild-type and D76N Î²2-Microglobulin. Journal of Biological Chemistry, 2016, 291, 9678-9689.	3.4	29
28	A novel mechanoâ€enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Molecular Medicine, 2015, 7, 1337-1349.	6.9	109
29	Capillary electrophoresis analysis of different variants of the amyloidogenic protein Î²₂â€microglobulin as a simple tool for misfolding and stability studies. Electrophoresis, 2015, 36, 2465-2472.	2.4	6
30	Decoding the Structural Bases of D76N ÃŸ2-Microglobulin High Amyloidogenicity through Crystallography and Asn-Scan Mutagenesis. PLoS ONE, 2015, 10, e0144061.	2.5	22
31	Enhanced toxicity of silver nanoparticles in transgenicCaenorhabditis elegansexpressing amyloidogenic proteins. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 221-228.	3.0	9
32	Class I Major Histocompatibility Complex, the Trojan Horse for Secretion of Amyloidogenic Î²2-Microglobulin. Journal of Biological Chemistry, 2014, 289, 3318-3327.	3.4	22
33	Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1539-1544.	7.1	91
34	Single Point Mutations Induce a Switch in the Molecular Mechanism of the Aggregation of the Alzheimerâ€™s Disease Associated Aî²₄₂ Peptide. ACS Chemical Biology, 2014, 9, 378-382.	3.4	25
35	Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 173-178.	3.0	24
36	Structure, Folding Dynamics, and Amyloidogenesis of D76N Î²2-Microglobulin. Journal of Biological Chemistry, 2013, 288, 30917-30930.	3.4	80

#	Article	IF	Citations
37	Reduction of conformational mobility and aggregation in W60G Î²₂â€microglobulin: assessment by ¹⁵N NMR relaxation. Magnetic Resonance in Chemistry, 2013, 51, 795-807.	1.9	10
38	Monitoring the Interaction between Î²2-Microglobulin and the Molecular Chaperone Î±B-crystallin by NMR and Mass Spectrometry. Journal of Biological Chemistry, 2013, 288, 17844-17858.	3.4	32
39	Hereditary Systemic Amyloidosis Due to Asp76Asn Variant Î²₂-Microglobulin. New England Journal of Medicine, 2012, 366, 2276-2283.	27.0	172
40	Fibrillogenesis of human Î²₂â€microglobulin in threeâ€dimensional silicon microstructures. Journal of Biophotonics, 2012, 5, 785-792.	2.3	8
41	C. elegans Expressing Human Î²2-Microglobulin: A Novel Model for Studying the Relationship between the Molecular Assembly and the Toxic Phenotype. PLoS ONE, 2012, 7, e52314.	2.5	21
42	Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic Î²2-microglobulin variant. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1314-1319.	7.1	108
43	The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: A possible impact on the natural history of the disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 87-93.	3.8	22
44	Effects of the Known Pathogenic Mutations on the Aggregation Pathway of the Amyloidogenic Peptide of Apolipoprotein A-I. Journal of Molecular Biology, 2011, 407, 465-476.	4.2	48
45	Dâ€strand perturbation and amyloid propensity in betaâ€2 microglobulin. FEBS Journal, 2011, 278, 2349-2358.	4.7	13
46	Screening of fibrillogenesis inhibitors of Î²2-microglobulin: Integrated strategies by mass spectrometry capillary electrophoresis and in silico simulations. Analytica Chimica Acta, 2011, 685, 153-161.	5.4	17
47	Enhanced molecular chaperone activity of the small heatâ€shock protein Î±Bâ€crystallin following covalent immobilization onto a solidâ€phase support. Biopolymers, 2011, 95, 376-389.	2.4	14
48	Effect of Tetracyclines on the Dynamics of Formation and Destructuration of Î²2-Microglobulin Amyloid Fibrils. Journal of Biological Chemistry, 2011, 286, 2121-2131.	3.4	87
49	The effects of an ideal Î²-turn on Î²-2 microglobulin fold stability. Journal of Biochemistry, 2011, 150, 39-47.	1.7	9
50	Native-unlike Long-lived Intermediates along the Folding Pathway of the Amyloidogenic Protein Î²2-Microglobulin Revealed by Real-time Two-dimensional NMR. Journal of Biological Chemistry, 2010, 285, 5827-5835.	3.4	55
51	Folding and Fibrillogenesis: Clues from Î²2-Microglobulin. Journal of Molecular Biology, 2010, 401, 286-297.	4.2	35
52	Fibrillar vs Crystalline Full-Length Î²-2-Microglobulin Studied by High-Resolution Solid-State NMR Spectroscopy. Journal of the American Chemical Society, 2010, 132, 5556-5557.	13.7	32
53	Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 115-121.	3.0	5
54	Proteomics in protein misfolding diseases. Clinical Chemistry and Laboratory Medicine, 2009, 47, 627-35.	2.3	8

#	Article	IF	Citations
55	Human beta-2 microglobulin W60V mutant structure: Implications for stability and amyloid aggregation. Biochemical and Biophysical Research Communications, 2009, 380, 543-547.	2.1	29
56	Topological investigation of amyloid fibrils obtained from Î²2-microglobulin. Protein Science, 2009, 11, 2362-2369.	7.6	53
57	Equilibrium Unfolding Thermodynamics of Î²2-Microglobulin Analyzed through Native-State H/D Exchange. Biophysical Journal, 2009, 96, 169-179.	0.5	20
58	Sulfonated molecules that bind a partially structured species of Î²₂â€microglobulin also influence refolding and fibrillogenesis. Electrophoresis, 2008, 29, 1502-1510.	2.4	18
59	The Controlling Roles of Trp60 and Trp95 in Î²2-Microglobulin Function, Folding and Amyloid Aggregation Properties. Journal of Molecular Biology, 2008, 378, 887-897.	4.2	82
60	Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins. Molecular Immunology, 2008, 45, 1519-1524.	2.2	2
61	DE loop mutations affect Î²2-microglobulin stability and amyloid aggregation. Biochemical and Biophysical Research Communications, 2008, 377, 146-150.	2.1	36
62	Heparin Strongly Enhances the Formation of Î²2-Microglobulin Amyloid Fibrils in the Presence of Type I Collagen. Journal of Biological Chemistry, 2008, 283, 4912-4920.	3.4	108
63	Â2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity. Nephrology Dialysis Transplantation, 2008, 24, 1176-1181.	0.7	31
64	The workings of the amyloid diseases. Annals of Medicine, 2007, 39, 200-207.	3.8	62
65	2â€DE and MALDIâ€TOFâ€MS for a comparative analysis of proteins expressed in different cellular models of amyotrophic lateral sclerosis. Electrophoresis, 2007, 28, 4320-4329.	2.4	13
66	A quantitative and qualitative method for direct 2â€DE analysis of murine cartilage. Proteomics, 2007, 7, 4003-4007.	2.2	20
67	Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 191-205.	3.0	124
68	Recombinant amyloidogenic domain of ApoA-I: Analysis of its fibrillogenic potential. Biochemical and Biophysical Research Communications, 2006, 351, 223-228.	2.1	18
69	Variants of Î²2-microglobulin cleaved at lysine-58 retain the main conformational features of the native protein but are more conformationally heterogeneous and unstable at physiological temperature. FEBS Journal, 2006, 273, 2461-2474.	4.7	19
70	Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. Protein Science, 2006, 16, 343-349.	7.6	24
71	Collagen Plays an Active Role in the Aggregation of Î²2-Microglobulin under Physiopathological Conditions of Dialysis-related Amyloidosis*. Journal of Biological Chemistry, 2006, 281, 16521-16529.	3.4	128
72	Solution structure of Î²2-microglobulin and insights into fibrillogenesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1753, 76-84.	2.3	25

#	Article	IF	Citations
73	Limited proteolysis in the investigation of Î²2-microglobulin amyloidogenic and fibrillar states. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1753, 44-50.	2.3	36
74	Proteomics of Î²2-microglobulin amyloid fibrils. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1753, 23-33.	2.3	36
75	Search of ligands for the amyloidogenic protein Î²2-microglobulin by capillary electrophoresis and other techniques. Electrophoresis, 2005, 26, 4055-4063.	2.4	17
76	Â2-Microglobulin isoforms display an heterogeneous affinity for type I collagen. Protein Science, 2005, 14, 696-702.	7.6	56
77	Purification and Characterization of SolubleCichorium intybusVar.silvestreLipoxygenase. Journal of Agricultural and Food Chemistry, 2005, 53, 6448-6454.	5.2	7
78	Pharmaceutical Strategies Against Amyloidosis: Old and New Drugs in Targeting a “Protein Misfolding Disease”. Current Medicinal Chemistry, 2004, 11, 1065-1084.	2.4	48
79	Properties of Some Variants of Human Î²2-Microglobulin and Amyloidogenesis. Journal of Biological Chemistry, 2004, 279, 9176-9189.	3.4	65
80	Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology, 2004, 126, 1416-1422.	1.3	70
81	Î²2-Microglobulin H31Y Variant 3D Structure Highlights the Protein Natural Propensity Towards Intermolecular Aggregation. Journal of Molecular Biology, 2004, 335, 1051-1064.	4.2	38
82	Conformational Switching and Fibrillogenesis in the Amyloidogenic Fragment of Apolipoprotein A-I. Journal of Biological Chemistry, 2003, 278, 2444-2451.	3.4	86
83	Structural and Folding Dynamic Properties of the T70N Variant of Human Lysozyme. Journal of Biological Chemistry, 2003, 278, 25910-25918.	3.4	23
84	Capillary electrophoresis investigation of a partially unfolded conformation of Î²2-microglobulin. Electrophoresis, 2002, 23, 918-925.	2.4	52
85	The solution structure of human Î²2â€microglobulin reveals the prodromes of its amyloid transition. Protein Science, 2002, 11, 487-499.	7.6	145
86	Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. Protein Science, 2001, 10, 187-199.	7.6	44
87	Detection of two partially structured species in the folding process of the amyloidogenic protein Î²2-microglobulin. Journal of Molecular Biology, 2001, 307, 379-391.	4.2	115
88	Dynamic of Î²2â€Microglobulin Fibril Formation and Reabsorption: The Role ofâ€ƒProteolysis. Seminars in Dialysis, 2001, 14, 117-122.	1.3	23
89	Hepatitis C virusâ€associated cryoglobulinaemicglomerulonephritis with delayed appearance ofmonoclonal cryoglobulinaemia. Nephrology Dialysis Transplantation, 2001, 16, 432-434.	0.7	5
90	A Partially Structured Species of Î²2-Microglobulin Is Significantly Populated under Physiological Conditions and Involved in Fibrillogenesis. Journal of Biological Chemistry, 2001, 276, 46714-46721.	3.4	137

#	Article	IF	Citations
91	Detection of fragments of Î²2-microglobulin in amyloid fibrils. Kidney International, 2000, 57, 349-350.	5.2	22